Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics.

The Food and Drug Administration (FDA) reviewed 300 new drug applications between 1995 and 2000. Of the 163 that included a sex analysis, 11 drugs showed a >40% difference in pharmacokinetics between males and females, which was listed on the product label, yet no dosing recommendations were made based on sex. Female sex has been shown to be a risk factor for clinically relevant adverse drug reactions. Would simply dosing females based on their different pharmacokinetics decrease the incidence of adverse events? The answer is not known. Sex-dependent pharmacodynamic effects have been identified. The role of pharmacokinetics vs. pharmacodynamics is unclear, as is the impact of pharmacogenetics on both. This review highlights a few specific examples in each area in which sex differences in pharmacokinetics and pharmacodynamics are important and provides recommendations for additional needed research.

[1]  M. Hughes,et al.  Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women , 2004, Antimicrobial Agents and Chemotherapy.

[2]  P. Pennell,et al.  The impact of pregnancy and childbirth on the metabolism of lamotrigine , 2004, Neurology.

[3]  A. Rane,et al.  Plasma concentration — effect relationship of metoprolol during and after pregnancy , 2004, European Journal of Clinical Pharmacology.

[4]  U. Gundert-Remy,et al.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations , 2004, European Journal of Clinical Pharmacology.

[5]  W. Jusko,et al.  Longitudinal effects of pregnancy on the pharmacokinetics of theophylline , 2004, European Journal of Clinical Pharmacology.

[6]  B. Ring,et al.  Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression , 2003, Journal of Pharmacology and Experimental Therapeutics.

[7]  H. Lennernäs,et al.  Multiple transport mechanisms involved in the intestinal absorption and first‐pass extraction of fexofenadine , 2003, Clinical pharmacology and therapeutics.

[8]  U. Schwarz,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C9 gene , 2003, European journal of clinical investigation.

[9]  I. Cascorbi.  Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication , 2003, European journal of clinical investigation.

[10]  Peter Neuhaus,et al.  Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.

[11]  P. Pennell.  Antiepileptic drug pharmacokinetics during pregnancy and lactation , 2003, Neurology.

[12]  K. Stȩpniewska,et al.  The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria , 2003, European Journal of Clinical Pharmacology.

[13]  K. Stȩpniewska,et al.  Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil , 2003, European Journal of Clinical Pharmacology.

[14]  S. Rathore,et al.  Digoxin and quality of life in heart failure. , 2003, Journal of cardiac failure.

[15]  Ernest Hodgson,et al.  Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. , 2003, Pharmacogenetics.

[16]  J. Lukas,et al.  Population pharmacokinetics of netilmicin in short-term prophylactic treatment. , 2003, British journal of clinical pharmacology.

[17]  H. Lee,et al.  Gender Differences in the Membrane Transport of Endogenous and Exogenous Compounds , 2003, Pharmacological Reviews.

[18]  S. Hayashi,et al.  Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women , 2003, AIDS.

[19]  U. Ekblad,et al.  Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation , 2003, Clinical pharmacology and therapeutics.

[20]  H. Krumholz,et al.  Digoxin therapy for heart failure: safe for women? , 2003, Italian heart journal : official journal of the Italian Federation of Cardiology.

[21]  Harlan M Krumholz,et al.  Association of serum digoxin concentration and outcomes in patients with heart failure. , 2003, JAMA.

[22]  J. Schwartz.  The Influence of Sex on Pharmacokinetics , 2003, Clinical pharmacokinetics.

[23]  A. Katchman,et al.  In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. , 2003, Cardiovascular research.

[24]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[25]  L. Benet,et al.  Sex‐related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P‐glycoprotein , 2002, Clinical pharmacology and therapeutics.

[26]  Harlan M Krumholz,et al.  Sex-based differences in the effect of digoxin for the treatment of heart failure. , 2002, The New England journal of medicine.

[27]  M. Anthony,et al.  Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. , 2002, Journal of women's health & gender-based medicine.

[28]  I. Leppik,et al.  Lamotrigine clearance during pregnancy , 2002, Neurology.

[29]  J. Daling,et al.  Body Weight and Risk of Oral Contraceptive Failure , 2002, Obstetrics and gynecology.

[30]  L. Benet,et al.  Changes in plasma protein binding have little clinical relevance , 2002, Clinical pharmacology and therapeutics.

[31]  G. Anderson.  Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase. , 2002, The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia.

[32]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[33]  Hartmut Derendorf,et al.  How Important Are Gender Differences in Pharmacokinetics? , 2002, Clinical pharmacokinetics.

[34]  L. Mofenson,et al.  Pharmacokinetics of Saquinavir-SGC in HIV-Infected Pregnant Women , 2001, HIV clinical trials.

[35]  Joo-Youn Cho,et al.  Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin , 2001, Clinical pharmacology and therapeutics.

[36]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[37]  I. Miyakawa,et al.  The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N‐acetyltransferase activities in humans , 2001, Clinical pharmacology and therapeutics.

[38]  J. Pezzullo,et al.  Drug-induced QT prolongation in women during the menstrual cycle. , 2001, JAMA.

[39]  Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. , 2001, British journal of clinical pharmacology.

[40]  M. Drici,et al.  Is Gender a Risk Factor for Adverse Drug Reactions? , 2001, Drug safety.

[41]  Donald J. Schuirmann,et al.  Pharmacokinetic analysis of bioequivalence trials: Implications for sex‐related issues in clinical pharmacology and biopharmaceutics , 2000, Clinical pharmacology and therapeutics.

[42]  M. Thase,et al.  Gender differences in treatment response to sertraline versus imipramine in chronic depression. , 2000, The American journal of psychiatry.

[43]  F. Aweeka,et al.  Pharmacokinetics of indinavir in HIV-positive pregnant women. , 2000, AIDS.

[44]  H. Saito,et al.  Hormonal regulation of organic cation transporter OCT2 expression in rat kidney , 2000, FEBS letters.

[45]  D. Flockhart,et al.  Greater quinidine‐induced QTc interval prolongation in women , 2000, Clinical pharmacology and therapeutics.

[46]  F. Follath,et al.  Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. , 2000, British journal of clinical pharmacology.

[47]  R. Kim,et al.  Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. , 1999, Pharmacogenetics.

[48]  D. Nicolau,et al.  Population Pharmacokinetics of Continuous Infusion Ceftazidime , 1999, Clinical pharmacokinetics.

[49]  C. Beasley,et al.  Olanzapine. Pharmacokinetic and pharmacodynamic profile. , 1999, Clinical pharmacokinetics.

[50]  R. A. Zeeuw,et al.  CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences , 1999, European Journal of Clinical Pharmacology.

[51]  S. Sviri,et al.  Phenotypic‐genotypic analysis of CYP2C19 in the Jewish Israeli population , 1999, Clinical pharmacology and therapeutics.

[52]  M. Jann,et al.  Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. , 1999, The Journal of clinical psychiatry.

[53]  N. Vermeulen,et al.  Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. , 1999, Critical reviews in toxicology.

[54]  S. Knowles,et al.  Gender Differences in Adverse Drug Reactions , 1998, Journal of clinical pharmacology.

[55]  U. Elkayam,et al.  Pharmacokinetic and Pharmacodynamic Evaluation of Atenolol during and after Pregnancy , 1998, Pharmacotherapy.

[56]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[57]  G. Koren,et al.  Pharmacokinetic Changes During Pregnancy and Their Clinical Relevance , 1997, Clinical pharmacokinetics.

[58]  M. Wadelius,et al.  Induction of CYP2D6 in pregnancy , 1997, Clinical pharmacology and therapeutics.

[59]  D W Nebert,et al.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.

[60]  S. Ekins,et al.  Examination of purported probes of human CYP2B6. , 1997, Pharmacogenetics.

[61]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[62]  H. Yamazaki,et al.  In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. , 1996, The Journal of pharmacology and experimental therapeutics.

[63]  J. Goldstein,et al.  Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans. , 1996, Pharmacogenetics.

[64]  K. Brøsen,et al.  Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. , 1996, Therapeutic drug monitoring.

[65]  B. Reigner,et al.  Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies , 1996, Antimicrobial agents and chemotherapy.

[66]  E. Schuetz,et al.  Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. , 1995, The Journal of pharmacology and experimental therapeutics.

[67]  B. Burchell,et al.  Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. , 1995, Life sciences.

[68]  F. Berthou,et al.  Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. , 1995, Pharmacogenetics.

[69]  L. Bertilsson,et al.  Geographical/Interracial Differences in Polymorphic Drug Oxidation , 1995, Clinical pharmacokinetics.

[70]  N. Narayanan,et al.  The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. , 1995, Pharmacogenetics.

[71]  W. Jaeger,et al.  Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.

[72]  F. Aoki,et al.  Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. , 1995, British journal of clinical pharmacology.

[73]  R. Slaughter,et al.  Vancomycin Pharmacokinetics in a Patient Population: Effect of Age, Gender, and Body Weight , 1994, Therapeutic drug monitoring.

[74]  D. Schrenk,et al.  The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. , 1994, Pharmacogenetics.

[75]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[76]  J. Schwartz,et al.  Aging of women alters S‐verapamil pharmacokinetics and pharmacodynamics , 1994, Clinical pharmacology and therapeutics.

[77]  T. Tomson,et al.  Epilepsy and Pregnancy: A Prospective Study of Seizure Control in Relation to Free and Total Plasma Concentrations of Carbamazepine and Phenytoin , 1994, Epilepsia.

[78]  B. Burchell,et al.  The Uridine Diphosphate Glucuronosyltransferase Multigene Family: Function and Regulation , 1994 .

[79]  M. Lehmann,et al.  Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs , 1993 .

[80]  A. Nafziger,et al.  Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. , 1993, The Journal of laboratory and clinical medicine.

[81]  F. Aoki,et al.  Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine , 1993, Clinical pharmacology and therapeutics.

[82]  M. Relling,et al.  Racial and gender differences in N‐acetyltransferase, xanthine oxidase, and CYP1A2 * activities , 1992, Clinical pharmacology and therapeutics.

[83]  E. Yukawa,et al.  Digoxin Population Pharmacokinetics from Routine Clinical Data: Role of Patient Characteristics for Estimating Dosing Regimens , 1992, The Journal of pharmacy and pharmacology.

[84]  K. Pittman,et al.  Effects of age and gender on pharmacokinetics of cefepime , 1992, Antimicrobial Agents and Chemotherapy.

[85]  J. Gross,et al.  Effect of age and sex on glomerular filtration rate measured by 51Cr-EDTA. , 1992, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[86]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[87]  B. Tang,et al.  Caffeine as a metabolic probe: Validation of its use for acetylator phenotyping , 1991, Clinical pharmacology and therapeutics.

[88]  F. Kristjánsson,et al.  Disposition of alprazolam in human volunteers. Differences between genders. , 1991, Acta pharmaceutica Nordica.

[89]  T. Ockhuizen,et al.  Application of a three-compartment model to a study of the effects of sex, alcohol dose and concentration, exercise and food consumption on the pharmacokinetics of ethanol in healthy volunteers. , 1991, Alcohol and alcoholism.

[90]  B. Zuckerman,et al.  High blood alcohol levels in women. , 2010, The New England journal of medicine.

[91]  H. Wynne,et al.  Effects of age and gender on in vitro properties of human liver microsomal monooxygenases , 1990, Clinical pharmacology and therapeutics.

[92]  C. J. Sells,et al.  Pharmacokinetics of anticonvulsants in pregnancy: Alterations in plasma protein binding , 1990, Epilepsy Research.

[93]  C. Lieber,et al.  High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. , 1990, The New England journal of medicine.

[94]  P. Vlasses,et al.  Effect of food on the absorption of enteric‐coated aspirin: Correlation with gastric residence time , 1987, Clinical pharmacology and therapeutics.

[95]  J. Puig,et al.  Sex differences in uric acid metabolism in adults: Evidence for a lack of influence of estradiol-17β (E2) on the renal handling of urate , 1986 .

[96]  C. Regårdh,et al.  Pregnancy‐induced increase in metoprolol metabolism , 1985, Clinical pharmacology and therapeutics.

[97]  D. Greenblatt,et al.  Diazepam kinetics in relation to age and sex. , 1981, Pharmacology.

[98]  J. Davison,et al.  Renal hemodynamics and tubular function in normal human pregnancy , 1980 .

[99]  G. Levy,et al.  Serum protein binding of drugs during and after pregnancy in humans , 1980, Clinical pharmacology and therapeutics.

[100]  H. Valkenburg,et al.  THE DISTRIBUTION OF SERUM URIC ACID VALUES IN A POPULATION UNSELECTED AS TO GOUT OR HYPERURICEMIA: TECUMSEH, MICHIGAN 1959-1960. , 1965 .